Detailed Narrative
Strong Q3 Performance and Raised Full-Year Guidance
Thermo Fisher Scientific reported an outstanding third quarter with 5% revenue growth to $11.12 billion and 10% adjusted EPS growth to $5.79. This strong performance, driven by excellent operational execution and the PPI Business System, enabled the company to raise its full-year 2025 revenue guidance to $44.1 billion-$44.5 billion and adjusted EPS guidance to $22.60-$22.86. The updated guidance reflects a $420 million increase in revenue and a $0.20 increase in adjusted EPS at the midpoint compared to the prior guide.
End-Market Dynamics and Geographic Performance
The pharma and biotech end market delivered mid-single-digit growth, led by bioproduction and Analytical Instruments. Academic and government revenue declined low single digits, showing modest improvement from Q2, with U.S. conditions similar to Q2 and China remaining pressured. Industrial and applied revenue grew mid-single digits, a sequential step-up. Diagnostics and healthcare revenue was down low single digits, primarily due to China, despite strong growth in transplant and immunodiagnostics. Geographically, North America grew low single digits, Europe and Asia Pacific grew mid-single digits, while China declined mid-single digits organically.
High-Impact Innovation and Product Launches
The company continued to drive innovation with several key product launches. In clinical next-gen sequencing, the Oncomine Dx Express Test received FDA approval as a companion diagnostic, and the Oncomine Comprehensive Assay+ was introduced for clinical research. For proteomics, the Olink Target 48 Neurodegeneration panel was launched. Analytical Instruments saw the unveiling of two new electron microscopes, the Talos 12 and Scios 3, and Chromeleon 7.4 software was launched to unify chromatography and mass spectrometry workflows, enhancing productivity for regulated labs.
Strategic Collaborations and Operational Productivity
Thermo Fisher announced a strategic collaboration with OpenAI to embed AI capabilities into products and services, focusing initially on improving clinical trial cycle times and leveraging data for drug development. ChatGPT Enterprise was also launched internally to boost productivity and customer engagement. Additionally, a strategic partnership with AstraZeneca BioventureHub in Sweden was formed for collaborative R&D, and a new Manufacturing Center of Excellence in Mebane, North Carolina, was opened to enhance U.S. supply chain resilience for laboratory pipette tips.
Active Capital Deployment and M&A
The company had a very active quarter for capital deployment, deploying approximately $4 billion in M&A and $1 billion in share repurchases. Acquisitions included the Filtration & Separation business from Solventum, now part of Life Sciences Solutions, and the Ridgefield, New Jersey sterile fill-finish site from Sanofi, expanding U.S. drug product manufacturing. Total share repurchases for the year reached $3 billion, alongside $160 million in dividends. Management noted a busy M&A pipeline focused on strategic fit and strong returns.
Onshoring and Reshoring Trends
Discussions with pharma and biotech customers indicate a quiet confidence in navigating government policies, including reshoring activities to the U.S. This trend is expected to benefit Thermo Fisher's channel business, bioproduction, and Analytical Instruments through new facility construction and expansions, primarily in 2027-2028. More immediately, leveraging the Pharma Services network, including the newly acquired Sanofi site, allows customers to move volume to the U.S. more cost-effectively, driving incremental demand for equipment and initial stocking inventory.